PolypDxTest™ Benefits

  • PolypDx™ is a revolutionary tool that is patient friendly and capable of identifying individuals at risk for developing colorectal cancer.
  • PolypDx™ was validated in a clinical trial of nearly 1000 patients, demonstrating a higher sensitivity than the fecal based tests (FOBT/ FIT) for detecting adenomatous polyps.
  • PolypDx™ requires one random urine sample, no unpleasant bowel cleansing preparation, nor unsanitary handling of stool.
  • PolypDx™ is fast and simple – just a small urine sample is required!

PolypDx™ is intended for individuals at average to moderate risk for colorectal cancer. Screening should be performed annually for those between 45 and 74 years.

The American Cancer Society estimates that:
  • over 140,000 new cases of colorectal cancer will occur in the United States in 2018.
  • with 97,220 new cases of colon cancer.
  • and 43,030 new cases of rectal cancer will occur.

Don’t Delay. Ask your Doctor if PolypDx™ is right for you!

Polyp and CRC Facts

  • Colorectal cancer is the second leading cause of cancer-related deaths in the United States and the third most common cancer.
  • Colorectal cancer is the third most commonly diagnosed cancer in the United States and it is the second and third most common cause of death from cancer in American men and women, respectively.
  • The relative 5-year survival rate for colorectal cancer when diagnosed at an early stage is about 90%, however only about 40% colorectal cancers are found at that early stage.
  • PolypDx™ identifies adenomatous polyps.
  • Polyps are common, occurring in 30-50% of adults.
  • Adenomatous polyps have the potential to become cancerous.
  • Two-thirds of all polyps are adenomatous polyps.
  • Adenomatous polyps can be completely and safely removed, thus preventing the progression into colorectal cancer.